The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

Jan. 29, 2024
Applicant:

Guangzhou Morui Pharmaceutical Technology Co., Ltd., Guangdong, CN;

Inventors:

Dousheng Wu, Guangdong, CN;

Yang Yang, Guangdong, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/63 (2006.01); C12N 15/86 (2006.01); A01K 67/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/4631 (2023.05); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 16/3023 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); A61K 2239/13 (2023.05); A61K 2239/21 (2023.05); A61K 2239/22 (2023.05); A61K 2239/55 (2023.05); C07K 2317/24 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01);
Abstract

Disclosed are a chimeric antigen receptor T (CAR-T) cell and a construction method thereof, and an antitumor drug. In the present application, aquaporin 3 (AQP3) is adopted as a novel anti-cancer target, and AQP3 is highly expressed in both tumor cells and tumor stromal cells and can mediate the transport of both water and glycerol, which is conducive to breakage of a physical barrier of a tumor and promotes CAR-T cells to well infiltrate into a tumor to kill the tumor. The chimeric antigen receptor (CAR) fusion protein of the present application can be used in the treatment of AQP3-positive malignant tumors, and especially, when used in the treatment of non-small cell lung cancer (NSCLC), the CAR fusion protein exhibits a significant therapeutic effect. In addition, when used in the treatment of lung cancer, the CAR fusion protein causes little damage to a normal tissue and exhibits high safety.


Find Patent Forward Citations

Loading…